Corvus Pharmaceuticals, Inc. CRVS
10.60 USD -0.04 (-0.38%)
Regular-session close
10.60 0.00 0.00%
After hours · Nov 16, 4:01 PM ET
10.43 Day range 11.05
6.39 52-week range 26.95
- YTD
- +37.66%
- 1 year
- +20.87%
News
seekingalpha.com Corvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product Corvus Pharmaceuticals offers a catalyst-rich, fully funded pipeline, highlighted by soquelitinib's potential for durable remission in atopic dermatitis and PTCL. Soquelitinib's post-treatment…
seekingalpha.com Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027 Corvus Pharmaceuticals maintains a "Strong Buy" rating, driven by soquelitinib's advancing clinical programs in r/r PTCL and autoimmune indications. The phase 3 trial for relapsed/refractory PTCL…
globenewswire.com Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership…
benzinga.com Corvus Pharma Q3 2026 Earnings Call Transcript Corvus Pharma (NASDAQ:CRVS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Corvus Pharma Q3 EPS $(0.22), Inline Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.22) per share which met the analyst consensus estimate. This is a 83.33 percent decrease over losses of $(0.12) per share from the same…
